EverSource Wealth Advisors LLC Increases Holdings in Bruker Co. (NASDAQ:BRKR)

EverSource Wealth Advisors LLC boosted its position in shares of Bruker Co. (NASDAQ:BRKR) by 41.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330 shares of the medical research company’s stock after acquiring an additional 390 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Bruker were worth $78,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BRKR. FMR LLC grew its holdings in Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after purchasing an additional 2,521,904 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its holdings in Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after purchasing an additional 666,617 shares during the last quarter. Point72 DIFC Ltd grew its holdings in Bruker by 4,875.9% during the 3rd quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock valued at $32,470,000 after purchasing an additional 460,722 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Bruker by 1,933.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after purchasing an additional 390,057 shares during the last quarter. Finally, State Street Corp grew its holdings in Bruker by 9.6% during the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after purchasing an additional 318,808 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Performance

Shares of BRKR stock opened at $47.14 on Wednesday. The company’s 50 day moving average is $53.10 and its 200 day moving average is $58.07. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a 52-week low of $44.11 and a 52-week high of $94.86. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of 62.03, a PEG ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, sell-side analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Monday, March 17th. Bruker’s dividend payout ratio is currently 26.32%.

Analysts Set New Price Targets

BRKR has been the topic of several analyst reports. Bank of America upped their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Barclays reduced their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus reduced their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research report on Friday, February 14th. Finally, UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.